CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback